Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis

This publication has 27 references indexed in Scilit:

• The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: A systematic review and meta-analysis
  Autoimmunity Reviews, 2023
• Identification of Three Different Phenotypes in Anti–Melanoma Differentiation–Associated Gene 5 Antibody–Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung Disease
  Arthritis & Rheumatology, 2023
• CXC chemokine ligand 16: a Swiss army knife chemokine in cancer
  Expert Reviews in Molecular Medicine, 2021
• CXCL16/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K/AKT/FOXO3a pathway
  International Immunopharmacology, 2020
• Serum KL‐6 level is a prognostic marker in patients with anti‐MDA5 antibody‐positive dermatomyositis associated with interstitial lung disease
  Journal of Clinical Laboratory Analysis, 2019
• ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease
  Clinical Rheumatology, 2018
• Anti–Melanoma Differentiation–Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis
  Arthritis Care & Research, 2015
• RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease
  Arthritis & Rheumatism, 2009
• Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositis
  Arthritis & Rheumatism, 2005
• A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo
  Nature Immunology, 2000